Hudson Bay Capital Management LP Adma Biologics, Inc. Transaction History

Hudson Bay Capital Management LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$3.12 - $4.22 $1.85 Million - $2.5 Million	-592,847 Reduced 97.75%	13,636 $50,000
Q1 2023 May 15, 2023	SELL	$3.01 - $3.87 $3.18 Million - $4.09 Million	-1,056,299 Reduced 63.53%	606,483 $2.01 Million
Q4 2022 Feb 14, 2023	SELL	$2.47 - $3.88 $875,573 - $1.38 Million	-354,483 Reduced 17.57%	1,662,782 $6.45 Million
Q3 2022 Nov 14, 2022	SELL	$2.03 - $2.86 $270,613 - $381,258	-133,307 Reduced 6.2%	2,017,265 $4.9 Million
Q2 2022 Aug 12, 2022	SELL	$1.43 - $2.2 $214,500 - $330,000	-150,000 Reduced 6.52%	2,150,572 $4.26 Million
Q1 2022 May 16, 2022	BUY	$1.28 - $1.83 $2.94 Million - $4.21 Million	2,300,572 New	2,300,572 $4.21 Million
Q4 2020 Feb 12, 2021	SELL	$1.8 - $2.56 $198,000 - $281,600	-110,000 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$2.04 - $3.74 $275,400 - $504,900	-135,000 Reduced 55.1%	110,000 $263,000
Q2 2020 Aug 12, 2020	BUY	$2.42 - $3.29 $592,900 - $806,050	245,000 New	245,000 $717,000

319

185M

917K

91.6K

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.91B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.